Literature DB >> 27826536

Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?

Wolfram C M Dempke1, Klaus Fenchel2.   

Abstract

Entities:  

Year:  2016        PMID： 27826536      PMCID： PMC5099520          DOI： 10.21037/tlcr.2016.10.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  17 in total

1.  Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Julie R Brahmer; Rosalyn A Juergens; Hossein Borghaei; Scott Gettinger; Laura Q Chow; David E Gerber; Scott A Laurie; Jonathan W Goldman; Frances A Shepherd; Allen C Chen; Yun Shen; Faith E Nathan; Christopher T Harbison; Scott Antonia
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

2.  Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.

Authors:  Kelly A Schats; Emily A Van Vré; Stefanie De Schepper; Carolien Boeckx; Dorien M Schrijvers; Wim Waelput; Erik Fransen; Isabelle Vanden Bempt; Bart Neyns; Ingrid De Meester; Mark M Kockx
Journal:  Histopathology       Date:  2016-10-10       Impact factor: 5.087

3.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

4.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

5.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

6.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  F A Shepherd; J Dancey; R Ramlau; K Mattson; R Gralla; M O'Rourke; N Levitan; L Gressot; M Vincent; R Burkes; S Coughlin; Y Kim; J Berille
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

7.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

Review 10.  Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?

Authors:  Wolfram C M Dempke; Ludger Sellmann; Klaus Fenchel; Klaus Edvardsen
Journal:  Anticancer Res       Date:  2015-11       Impact factor: 2.480
View more
  1 in total

1.  Long non-coding RNA DGCR5 is involved in the regulation of proliferation, migration and invasion of lung cancer by targeting miR-1180.

Authors:  En-Guo Chen; Ji-Song Zhang; Shan Xu; Xiao-Jing Zhu; Hui-Hui Hu
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.